AJIC: American Journal of Infection Control
Volume 35, Issue 9 , Pages 606-612 , November 2007

Clinical and molecular epidemiology of community-onset, extended-spectrum β-lactamase-producing Escherichia coli infections in Thailand: A case-case-control study

  • Anucha Apisarnthanarak, MD

      Affiliations

    • Division of Infectious Diseases, Faculty of Medicine, Thammasart University Hosptial, Pratumthani, Thailand
    • Corresponding Author InformationAddress correspondence to Anucha Apisarnthanarak, MD, Division of Infectious Diseases, Faculty of Medicine, Thammasart University Hospital, Pratumthani, Thailand 12120.
    • ,
  • Patarachai Kiratisin, MD, PhD

      Affiliations

    • Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
    • ,
  • Piyawan Saifon, BSc

      Affiliations

    • Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
    • ,
  • Rungrueng Kitphati, MD

      Affiliations

    • Division of Science, Thai National Institute of Health, Nonthaburi, Thailand
    • ,
  • Surang Dejsirilert, MSc

      Affiliations

    • Division of Science, Thai National Institute of Health, Nonthaburi, Thailand
    • ,
  • Linda M. Mundy, MD

      Affiliations

    • Saint Louis University School of Public Health, St. Louis, MO

References 

  1. Knothe H, Shah P, Kremery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole, and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection. 1983;11:315–317
  2. Quinn JP, Miyashiro D, Sahm D, Flamm R, Bush K. Novel plasmid-mediated β-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother. 1989;33:1451–1456
  3. Jacoby GA, Medeiros AA, O'Brien TF, Pinto ME, Jiang H. Broad-spectrum transmissible β-lactamases. N Engl J Med. 1988;319:723–724
  4. Meyer KS, Urban C, Eagen JA, Berger BJ, Rahall JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med. 1993;119:353–358
  5. Rice LB, Willey SH, Papanicolaou GA, Medeiros AA, Eliopoulos GM, Moellering RC, et al. Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother. 1990;34:2200–2209
  6. Burwen DR, Banerjee SN, Gaynes RP. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. The National Nosocomial Infections Surveillance System. J Infect Dis. 1994;170:1622–1625
  7. Itokazu GS, Quinn JP, Bell-Dixon C, Kahan FM, Weinstein RA. Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin Infect Dis. 1996;23:779–784
  8. Nijssen S, Florijn A, Bonten MJM, Schmitz FJ, Verhoef J, Fluit AC. β-Lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates. Int J Antimicrob Agents. 2004;24:585–591
  9. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001;14:933–951
  10. Gniadkowsky M. Evolution and epidemiology of extended-spectrum β-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infect. 2001;7:597–608
  11. Borer A, Gilad J, Menashe G, Peled N, Riesenberg K, Schlaeffer F. Extended-spectrum β-lactamase-producing Enterobacteriaceae strains in community-acquired bacteremia in Southern Israel. Med Sci Monit. 2002;8:CR44–CR47
  12. Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, et al. Risk factors for the development of extended-spectrum β-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis. 2004;23:163–167
  13. Cormican M, Morris D, Corbett-Feeney G, Flynn J. Extended spectrum β-lactamase production and fluoroquinolone resistance in pathogens associated with community acquired urinary tract infection. Diagn Microbiol Infect Dis. 1998;32:317–319
  14. Daza R, Gutierrez J, Piedrola G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int J Antimicrob Agents. 2001;18:211–215
  15. De Moüy D, Cavallo JD, Fabre R. Les entérobactéries isolées d'infections urinaires en pratique de ville: étude AFORCOPIBIO 1995. Med Mal Infect. 1997;27:642–645
  16. Goldstein FW. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections in France. Multicentre Study Group. Eur J Clin Microbiol Infect Dis. 2000;19:112–117
  17. Heseltine P. Has resistance spread to the community?. Clin Microbiol Infect. 2000;6:11–16
  18. Hryniewicz K, Szczypa K, Sulikowska A, Jankowski K, Betlejewska K, Hryniewicz W. Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland. J Antimicrob Chemother. 2001;47:773–780
  19. Lescure FX, Eveillard M, Douadi Y, Eb F. Community-acquired multiresistant bacteria: an emerging problem?. J Hosp Infect. 2001;49:149–151
  20. Liu CP, Wang NY, Lee CM, Weng LC, Tseng HK, Liu CW, et al. Nosocomial and community-acquired Enterobacter cloacae bloodstream infection: risk factors for and prevalence of SHV-12 in multiresistant isolates in a medical centre. J Hosp Infect. 2004;58:63–77
  21. Millar MR, Walsh TR, Linton CJ, Zhang S, Leeming JP, Bennett PM. Carriage of antibiotic-resistant bacteria by healthy children. J Antimicrob Chemother. 2001;47:605–610
  22. Mirelis B, Navarro F, Miro E, Mesa RJ, Coll P, Prats G. Community transmission of extended-spectrum β-lactamase. Emerg Infect Dis. 2003;9:1024–1025
  23. Munday CJ, Whitehead GM, Todd NJ, Campbell M, Hawkey PM. Predominance and genetic diversity of community- and hospital-acquired CTX-M extended-spectrum β-lactamases in York, UK. J Antimicrob Chemother. 2004;54:628–633
  24. Péan Y, Goldstein FW, Guerrier ML. Sensibilité aux β-lactamines des bactéries isolées en ville et àl'hôpital au cours d'une enquête multicentrique française. Antibiotiques. 1999;1:165–170
  25. Pitout JD, Hanson ND, Church DL, Laupland KB. Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum β-lactamases: importance of community isolates with blaCTX-M genes. Clin Infect Dis. 2004;38:1736–1741
  26. Rodriguez-Baño J, Navarro MD, Romero L, Martínez-Martínez L, Muniain MA, Perea EJ, et al. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol. 2004;42:1089–1094
  27. Tan BH, Tan AL. Community-acquired bacteremia with an ESBL-producing Escherichia coli strain: a case report. Int J Infect Dis. 2002;6:318–319
  28. Valverde A, Coque TM, Sanchez-Moreno MP, Rollan A, Baquero F, Canton R. Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol. 2004;42:4769–4775
  29. Calbo E, Romaný V, Xercavins M, Gómez L, Vidal CG, Quintana S, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harboring extended-spectrum β-lactamases. J Antimicrob Chemother. 2005;57:780–783
  30. Ben-Ami R, Schwaber MJ, Navon-Venezia S, Schwartz D, Giladi M, Chmelnitsky I, et al. Influx of extended-spectrum β-lactamases-producing enterobacteriaceae into the hospital. Clin Infect Dis. 2006;42:925–934
  31. Dejsirilert S, Apisarnthanarak A, Kitphati R, Mundy LM. The status of antimicrobial resistance in Thailand among gram-negative pathogens in bloodstream infections: NARST data, 2000-2003 (abstract FP-A-3). In: Program and abstracts of the 9th Western Pacific Congress on Chemotherapy and Infectious Diseases, Bangkok, 2004. Abstract FP-A-3. p. 185.
  32. Apisarnthanarak A, Danchaivijitr S, Bailey TC, Fraser VJ. Inappropriate antibiotic use in a tertiary care center in Thailand: an incidence study and review of experience in Thailand. Infect Control Hosp Epidemiol. 2006;27:416–420
  33. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128–140
  34. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis. 2000;31(Suppl 4):S131–S138
  35. CLSI (NCCLS) . Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement, M100–MS16. Wayne, PA: Clinical Laboratory Standards Institute; 2006;
  36. Coque TM, Oliver A, Perez-Diaz JC, Baquero F, Canton R. Genes encoding TEM-4, SHV-2, and CTX-M-10 extended-spectrum β-lactamases are carried by multiple Klebsiella pneumoniae clones in a single hospital (Madrid, 1989 to 2000). Antimicrob Agents Chemother. 2002;46:500–510
  37. Oliver A, Perez-Diaz JC, Coque TM, Baquero F, Canton R. Nucleotide sequence and characterization of a novel cefotaxime-hydrolyzing β-lactamases (CTX-M-10). Antimicrob Agents Chemother. 2001;45:612–620
  38. Tenover FC, Arbeit RD, Goering RV, Michelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33:2233–2239
  39. Harris AD, Samore MH, Lipsitch M, Kaye KS, Perencevich E, Carmeli Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis. 2002;34:1558–1563
  40. Harris AD. Control group selection is an important but neglected issue in studies of antibiotic resistance. Ann Intern Med. 2000;132:925
  41. Kaye KS, Harris AD, Samore M, Carmeli Y. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol. 2005;26:346–351
  42. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006;42(Suppl 2):S82–S89
  43. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32:1162–1171
  44. Kiratisin P, Apisarnthanarak A, Saifon P, Laesripa C, Kitphati R, Mundy LM. The emergence of a novel ceftazidime-hydrolyzing extended-spectrum β-lactamase, CTX-M-55, in both community-onset and hospital-acquired infections in Thailand. Diag Microbiol Infect Dis. 2007;58:349–355

 Supported in part by an award from the Thammasart University Alumni Fund (to A.A.).

 Conflicts of interest: None.

PII: S0196-6553(07)00620-7

doi: 10.1016/j.ajic.2007.05.008

AJIC: American Journal of Infection Control
Volume 35, Issue 9 , Pages 606-612 , November 2007

Article Tools

* Image Usage & Resolution